Catalyst Pharmaceuticals Inc (CPRX) was Upgraded by Piper Jaffray to ” Overweight”. Earlier the firm had a rating of “Neutral ” on the company shares. Piper Jaffray advised their investors in a research report released on Oct 5, 2016.
Catalyst Pharmaceuticals Inc closed down -0.03 points or -2.61% at $1.12 with 2,43,688 shares getting traded on Tuesday. Post opening the session at $1.15, the shares hit an intraday low of $1.09 and an intraday high of $1.19 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jul 12, 2016, Charles B O’keeffe (director) purchased 20,000 shares at $0.81 per share price. According to the SEC, on Jun 14, 2016, Donald A Denkhaus (director) purchased 50,000 shares at $0.65 per share price. On Jun 14, 2016, Patrick J Mcenany (CEO) purchased 105,300 shares at $0.65 per share price, according to the Form-4 filing with the securities and exchange commission.
Catalyst Pharmaceuticals Inc. formerly Catalyst Pharmaceutical Partners Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse CPP-109 and CPP-115. Firdapse is used for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). CPP-115 is used for the treatment of addiction and epilepsy. CPP-109 is used to treat addiction. The Company is conducting a Phase III trial to determine the safety and efficacy of Firdapse in the treatment of LEMS. CPP-115 has been granted Orphan Drug Designation by the food and drug administration (FDA) for the treatment of infantile spasms and Orphan Medicinal Product Designation in the European Union for West syndrome (a form of infantile spasms).